Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANNEXA-A: Andexanet Alfa for Apixaban Reversal
NCT02207725Phase 3Completed
- Sponsor
- Portola Pharmaceuticals
- Start
- Mar 2014
- Primary completion
- Apr 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hemorrhage comparing Andexanet Alfa with Placebo (2 arms). Primary endpoint: Percent Change From Baseline in Anti-fXa Activity at the Nadir. Started Mar 2014; status: completed.
02
Drugs
andexanet alfa
03
Conditions
hemorrhage
Beyond the preview
Go deeper on NCT02207725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02207725.